Despite a pick-up in the pace of approvals the last few years, treatments are available for only 5% of the roughly 7,000 rare diseases.
Health data is governed by laws nearly 25 years old, and as more types of health data are created, from fitness to biometric to genetic data, Washington can’t keep up.
Sander Flaum discusses the DISARM act and how we can fight back against antibiotic resistance.
Payers spoiled the debut of the first two PCSK9 drugs from Sanofi and Amgen. A third is poised for approval — but if history is any guide, its U.S. market-access path will be anything but smooth.
We analyze three winning rare disease campaigns that illustrate the challenges and opportunities that come with operating in such a difficult realm.
Tom Harrison cofounded Harrison & Star.
As part of the Medical Advertising Hall of Fame’s annual awards program, agencies nominate their brightest young stars as Future Famers.
Larry Lesser cofounded Medicus Communications and ApotheCom Associates.
John Kamp was executive director for the Coalition for Healthcare Communication.
The FDA granted Pfizer’s Ibrance a label indication based on real-world data from men using the drug off-label to treat their breast cancer.
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
OptimizeRx’s Chris DiCostanzo and Rebecca Love explain the value of reaching patients and HCPs when it matters most.
Talking Medicines’ Jo Halliday discussed how the pharmaceutical sector can better understand the voice of the patient.
Learn about Intouch Group’s journey to foster I+D so that its inclusive culture translates into inclusive healthcare marketing.
Any EHR provider delivering a quality solution should be able to answer these six questions.
Please login or register first to view this content.